Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep‐Vein Thrombosis as First‐Line Therapy (AMPLIFY) Trial

BACKGROUND: In the Apixaban for the Initial Management of Pulmonary Embolism and Deep‐Vein Thrombosis as First‐Line Therapy (AMPLIFY) trial, apixaban was noninferior to enoxaparin/warfarin in preventing recurrent symptomatic venous thromboembolism (VTE) or venous thromboembolism–related death, with...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xianchen, Johnson, Margot, Mardekian, Jack, Phatak, Hemant, Thompson, John, Cohen, Alexander T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845271/
https://www.ncbi.nlm.nih.gov/pubmed/26627879
http://dx.doi.org/10.1161/JAHA.115.002340

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845271/
https://www.ncbi.nlm.nih.gov/pubmed/26627879
http://dx.doi.org/10.1161/JAHA.115.002340

Ejemplares similares